Published in final edited form as:

Tetrahedron Lett. 2015 January 1; 56(1): 109–114. doi:10.1016/j.tetlet.2014.11.029.

Total synthesis of trifluorobutyryl-modified, globally protected sialyl Lewis x by a convergent [2+2] approach

Gizem Akçay^a, John Y. Ramphal^{b,‡}, Marc d'Alarcao^{b,*}, and Krishna Kumar^{a,†,*}

^aDepartment of Chemistry, Tufts University, Medford, Massachusetts 02155, United States

^bDepartment of Chemistry, San José State University, San José, California 95192, United States

Abstract

Structural and quantitative changes in the expression of sialic acid residues on the surface of eukaryotic cells profoundly influence a broad range of biological processes including inflammation, antigen recognition, microbial attachment, and tumor metastasis. Uptake and incorporation of sialic acid analogues in mammalian cells enable structure-function studies and perturbation of specific recognition events. Our group has recently shown that a trifluorobutyryl-modified sialic acid metabolite diminishes the adhesion of mammalian cells to E and P-selectin, presumably by leading to the expression of fluorinated sLe^x epitopes on cell surfaces, and interfering with the sLe^x-selectin interactions that are well known in mediating tumor cell migration.¹ For studies directed towards understanding the molecular basis of this reduced adhesion, chemical synthesis of trifluorobutyrylated sialyl Lewis x (C₄F₃-sLe^x) was crucial. We have developed a highly efficient [2+2] approach for the assembly of C₄F₃-sLe^x on a preparative scale that contains versatile protective groups allowing the glycan to be surface immobilized or solubilized as needed for biophysical studies to investigate selectin interactions. This strategy can, in principle, be used for preparation of other *N*-modified sLe^x analogues.

Keywords

sialic acid; sialyl Lewis X; sialylation; glycosylation; fluorinated carbohydrates; convergent synthesis; cellular adhesion; cancer metastasis

© 2014 Elsevier Ltd. All rights reserved.

*CORRESPONDING AUTHORS: Krishna Kumar <krishna.kumar@tufts.edu>; Fax: +1 617 627 3443 and Marc d'Alarcao <marc.dalarcao@sjsu.edu>; Fax: +1 408 924 4945.

[†]Cancer Center, Tufts Medical Center, Boston, Massachusetts 02111, United States

[‡]InterMune, Brisbane, California 94005, United States

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

5. Supplementary data Supplementary data associated with this article can be found in the online version.

1. Introduction

Sialic acids (*N*-acetylneuraminic acids) are the most prevalent monosaccharides found at the termini of glycoconjugates on cell surfaces and are involved in many biologically critical ligand-receptor interactions.² Sialylation patterns of cell surfaces are dynamic in order to accommodate specific carbohydrate-protein interactions. Most of the diversity is generated by substitution patterns at the C4, C5, C7, C8 and C9 positions associated with linkage variation.³ In humans, sialic acids appear principally in the form of α (2-3)-linked galactosides or α (2-6)-linked 2-acetamino-2-deoxygalactosides.^{4,5}

Modification of siaologlycoconjugates in living cells by metabolic incorporation of non-natural sialic acids expands this structural diversity, and proffers the ability to interfere with binding events that are implicated in disease development.⁶⁻⁸ To investigate the therapeutic potential of sialic acid analogues in cancer progression by targeting selectin-mediated cell adhesion, we designed fluorinated sialic acid precursors. Selectins are membrane-bound glycoproteins expressed on a variety of cells including activated vascular endothelium and leukocytes, and they interact with sLe^x displayed on the surface of their partner cells. This facilitates the recruitment of leukocytes into inflamed tissues. Cancer cells utilize the same mechanism of selectin adhesion in order to exit the bloodstream and form metastatic tumors at different sites. Notably, high levels of sialosides, particularly sLe^x on cell surfaces have been shown to correlate with malignant transformation of gastrointestinal, pancreatic and breast cancer cells.⁹⁻¹²

In studies directed towards inhibition of sLe^x-selectin interactions, modified sLe^x structures that have higher binding affinities for selectins have been generated.¹³ However, inhibition of selectin-mediated cell-cell interactions via monovalent sLe^x analogues appears to be limited since efficient binding to selectins requires multivalent interactions in the biological context. Our approach alters cellular adhesion through glycoengineering of surface sialoconjugates using synthetic fluorinated sialic acids. The observed decrease in adhesion of these engineered cells was most pronounced with the trifluorobutyryl modified sialic acid precursor.¹ We hypothesized that fluorination of the endogenous sLe^x ligand on cell surfaces may reduce selectin-mediated cellular adhesion by lowering the affinity of the glycan towards selectins. Thus, we are particularly interested in characterizing trifluorobutyrylated sLe^x-selectin binding *in vitro*. Accordingly, we focused our efforts on the synthesis of C₄F₃-sLe^x.

The assembly of the tetrasaccharide sLe^x has been a nontrivial task for synthetic chemists, as it requires selective formation of glycosidic bonds with highly functionalized substrates. Persistent challenges in synthesizing sLe^x include the spatial proximity of the galactose and fucose in positions C-4 and C-3 of *N*-acetylglucosamine,¹⁴ resulting in low reactivity of C4-OH or C3-OH in glycosylation reactions, the pronounced acid lability of the α -L-fucose linkage,¹⁵ and difficulties associated with chemical sialylation.^{2,16} Choosing a suitable set of orthogonal protecting groups to enable anomeric control and high yielding glycosylations has been key to several successful sLe^x syntheses reported to date. Although a variety of chemical and chemo-enzymatic methods are available for the synthesis of naturally

occurring sLe^x and sLe^x-containing complex structures¹⁷⁻²¹, only few methods have been reported to make *N*-modified sialic acid containing oligosaccharides²²⁻²⁴ and no efficient protocols exist for the preparation of *N*-modified sLe^x analogues. We devised a versatile solution phase convergent chemical strategy for the construction of *N*-substituted unnatural sLe^x structures. Key features of our synthesis include simple and efficient protecting group manipulation and orchestrated use of glycosyl halide, phosphite and trifluoroimide donors to ensure sufficient reactivity and stereoselectivity. Furthermore, our synthetic route offers the opportunity to install a wide range of C-5 modifications on the sialic acid that would allow construction of *N*-modified sLe^x or more complex oligosaccharide libraries.

2. Results and Discussion

For the synthesis of desired tetrasaccharide **I**, not only must the strategy afford suitable quantities but it also must accommodate structural variation to allow preparation of analogue structures. We envisioned that sufficient quantities of such a complex target could be obtained by employing a convergent approach that uses orthogonally protected building blocks that can be assembled into the target by using a minimal number of synthetic steps. In planning the synthetic route, target tetrasaccharide **I** was disconnected into two blocks at the Galβ(1-4)GlcNAc linkage, generating two disaccharide precursors. Accordingly, the final tetrasaccharide structure can be assembled through a [2+2] glycosylation of novel building blocks, disaccharide donor **II** and disaccharide acceptor **III**.

Important features of the disaccharide acceptor **III** include, (1) the protecting group pattern on the fucose building block, that improves stability of the α fucoside linkage while preserving a non-participating group at 2-OH to enable a 1,2-*cis*-L-fucopyranosyl glycosidic bond, (2) a 4,6-*O*-benzylidene acetal protection on the glucosamine building block, that provides a 6-*O*-benzyl substituted disaccharide acceptor that is sterically less demanding at the site of the [2+2] glycosylation, and (3) the presence of a flexible *O*-pentenyl functionality at the anomeric oxygen that allows access to soluble sLe^x constructs by simple removal of the *O*-pentenyl moiety through aqueous *N*-bromosuccinimide (NBS) treatment or enables surface conjugation of the compounds via thiol linkers. A thiol-terminated linker can be introduced by addition of thiolacetic acid to the olefin in the presence of azobisisobutyronitrile (AIBN).²⁵ Other types of linkers can also be presented via olefin metathesis reaction.^{26,27}

For the construction of disaccharide acceptor **III**, we proposed new building blocks **9** and **17** that can be prepared in a facile manner, using both reported and new intermediate monosaccharides. The preparation of fucosyl donor **9** started with conversion of L-fucose tetraol to the peracetylated derivative **1**. The reaction of tetraacetate **1** with thiophenol (PhSH) in the presence of BF₃·Et₂O afforded thioglycoside **2**²⁸ in 85% yield. Next, global deprotection of *O*-acetyl groups followed by 3,4-ortho ester formation using 2,2-dimethoxypropane with *p*-toluenesulfonic acid monohydrate (pTsOH·H₂O) generated derivative **4**.²⁸ Benzylolation of the 2-OH and removal of the isopropylidene protection gave diol **6**¹⁹ in high yield. Pivaloate esters were installed on the free hydroxyls by treating **6** with pivaloyl chloride and DMAP. A final deprotection step with NBS in aqueous medium furnished the reducing sugar **8**²⁹ in 79% yield. Glycosyl fluoride donors in combination with

promoters, stannous chloride (SnCl_2) and silver perchlorate (AgClO_4) are often used to achieve good α -stereoselectivity.^{30,31} Thus, we synthesized fucosyl fluoride **9** from reaction of **8** with diethylaminosulfur trifluoride (DAST) at low temperature.

A carefully designed protection strategy enabled access to the *N*-acetyl glucosamine acceptor **17** efficiently. Glycosylation of acetate **10** with pentene-1-ol mediated by TMSOTf gave the known compound **11**.³² Zemlén deacetylation followed by addition of the 4,6-*O*-benzylidene protection using benzaldehyde dimethyl acetal and *p*-toluenesulfonic acid resulted in previously reported intermediate **13**.³³ Next, the free alcohol was masked by treatment with levulinic acid in the presence of an activating system composed of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI) and DMAP to yield **14**. Regioselective opening of the benzylidene acetal at 4-OH with triethylsilane and $\text{BF}_3 \cdot \text{Et}_2\text{O}$ followed by benzoyl protection of the free alcohol and finally the cleavage of the levulinate ester via aqueous hydrazine afforded glycosyl acceptor **17** in 69% yield starting from **14** (Scheme 3).

The coupling of fucosyl donor **9** with acceptor **17** provided **18** in 85% yield. Disaccharide **18** was then subjected to optimized reaction conditions with NaOMe for selective removal of the benzoyl ester in the presence of pivaloyl esters, generating disaccharide acceptor **III** in 83% yield (Scheme 4).

The next stage of the synthesis entailed the preparation of disaccharide donor **II**. We envisaged that *N*-Troc protection of the sialic acid amine would be suitable because selective Troc deprotection can be accomplished under mild acidic or neutral conditions to produce a sialic acid α (2-3)-galactose intermediate bearing a free amino group for derivatization. The additional advantage of this modification would be improved sialylation yields as reported by Hanashima *et al.*³⁴ For the construction of *N*-Troc sialic acid α (2-3)-galactose precursor, we explored the utility of both aryl sulfide and phosphite-based sialic acid donors. Aryl sulfide-based donors that are associated with the NIS/TfOH glycosylation system offer the advantage of being highly stable and nonhygroscopic. While phosphite-based donors are relatively less stable, they exhibit high activity when a catalytic amount of promoter is used and result in predominant formation of the α product.^{35,36}

Synthesis of sialic acid donors **23**³⁵ and **24**³⁴ are outlined in Scheme Scheme 5. Glycosyl chloride **19** was treated with thiocresol in the presence of *N,N*-diisopropylethylamine (DIEA), affording the corresponding thioglycoside **20** in 71% yield. Conversion of thioglycoside **20** to **21** via a single de-acetylation step followed by Troc protection of the free amine resulted in poor yields, likely due to the formation of a bicyclic lactam side product. This side reaction was prevented by a two-step de-acetylation procedure. Fully de-acetylated amino intermediate **21** was obtained after treatment of **20** with potassium cyanide (KCN) in methanol at ambient temperature for selective de-*O*-acetylation followed by warming at reflux with methanolic methanesulfonic acid to remove the *N*-acetyl function at the C-5 position. The resulting crude amine salt was directly used in the next reaction to generate tetra-ol **22** in 95% yield over three steps. Global acetylation of **22** afforded sialic acid donor **23** in 88% yield. Sialic acid phosphite donor **24** was prepared by removal of the thiocresol group followed by treatment with dibenzyl diisopropyl-phosphoramidite and imidazole in 60% yield.

Next, glycosylation reactions were performed to test the performance of sialic acid donors using 4,6-di-*O*-benzyl-D-galactal **25**³⁴ as the acceptor. NIS/TfOH-mediated coupling of thioglycoside **23** with **25** was attempted in acetonitrile at low temperature, but no desired product could be isolated. The glycosylation reaction between phosphite donor **24** and alcohol **25** however, in the presence of TMSOTf at -78°C , produced known α -sialoside **26** in 86% yield. The transformation of disaccharide **26** to corresponding sialic acid $\alpha(2-3)$ -galactose **28** was accomplished in two steps as described previously.³⁴ *N*-Troc removal was performed by treatment of **28** with activated zinc powder and 10% formic acid in acetonitrile to furnish the free amine **29** in quantitative yield. With the key intermediate **29** in hand, we sought an efficient procedure for appending the desired fluoroalkyl function at C-5. Initially we attempted to prepare the 5-trifluorobutyryl modified sialic acid $\alpha(2-3)$ -galactose by reaction of **29** with *N*-hydroxysuccinimidyl 4,4,4-trifluorobutyrate in the presence of DIEA. The results were unsatisfactory due to sluggish reactivity. However, treatment of **29** with the HOBt ester of 4,4,4-trifluorobutyric acid in the presence of DIEA at 0°C , provided the desired fluoralkyl product **30** in 86% yield.

Having established an expedient synthesis of trifluorobutyryl modified sialic acid $\alpha(2-3)$ -galactose, the conversion of this product to an activated disaccharide donor was investigated. For this purpose, disaccharide **30** was treated with hydrazine acetate to selectively remove the anomeric acetate and generate hemiacetal **31**. Considering the good balance of stability and reactivity found with *N*-phenyl trifluoroacetimidate donors in complex oligosaccharide synthesis, we chose this methodology.³⁷⁻³⁹ Treatment of **31** with *N*-phenyl trifluoroacetimidoyl chloride ($\text{CF}_3\text{C}(\text{NPh})\text{Cl}$) in the presence of CsCO_3 produced the corresponding trifluorobutyryl-modified sialic acid $\alpha(2-3)$ -galactose donor **II** in 92% yield.

Finally with both disaccharide building blocks in hand, we explored the viability of [2+2] glycosylation reaction to access trifluorobutyryl modified sLe^x **I**. We screened a variety of glycosylation conditions using promoter systems including TMSOTf, $\text{Yb}(\text{OTf})_3$, acid washed molecular sieves and $\text{BF}_3\cdot\text{Et}_2\text{O}$. The best result was with $\text{BF}_3\cdot\text{Et}_2\text{O}$ mediated [2+2] coupling affording the desired tetrasaccharide **I** in 38% yield (Table 1, entry 10).

3. Conclusion

We have demonstrated the utility of a convergent [2+2] strategy in the synthesis of a versatile trifluorobutyryl-modified sLe^x analogue, **I**. This material can be used to generate the soluble fluorinated tetrasaccharide C_4F_3 -sLe^x suitable for ITC studies to determine the binding constant with P- and E-selectin. In parallel, **I** can be immobilized on a maleimide functionalized surface after selective modification of the *O*-pentenyl moiety into a thiol function, followed by removal of all the protecting groups for SPR binding studies.⁴⁰⁻⁴³ Moreover, **I** could be elaborated further to obtain the high affinity P-selectin glycoprotein ligand 1 (PSGL1). The results of these biophysical studies will be reported in due course.

The chemical strategy and the key building blocks described in this work should be particularly useful for preparative scale synthesis of biologically relevant oligosaccharides with unnatural sialic acid residues and offer a way to study interactions of *N*-5 (sialic acid)

modified sLe^x epitopes for a variety of interrogations using biophysical and cell biological techniques.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

This work was supported in part by the National Institutes of Health (CA125033 to K.K. and M.D.) and by Tufts University. The ESI-MS and NMR facilities at Tufts and the MS facility at SJSU are supported by grants from the National Science Foundation (0320783, 0821508, and 0923573, respectively).

6. References

- (1). Dafik L, Dalarcao M, Kumar KJ. *Med. Chem.* 2010; 53:4277.
- (2). Kiefel MJ, Von Itzstein M. *Chem. Rev.* 2002; 102:471. [PubMed: 11841251]
- (3). Chen X, Varki A. *ACS Chem. Biol.* 2010; 5:163. [PubMed: 20020717]
- (4). Rosenberg SA, Einstein AB Jr. *J. Cell Biol.* 1972; 53:466. [PubMed: 4502785]
- (5). De Meo C, Priyadarshani U. *Carbohydr. Res.* 2008; 343:1540. [PubMed: 18452900]
- (6). Jacobs CL, Goon S, Yarema KJ, Hinderlich S, Hang HC, Chai DH, Bertozzi CR. *Biochemistry.* 2001; 40:12864. [PubMed: 11669623]
- (7). Lemieux GA, Bertozzi CR. *Chem. Biol.* 2001; 8:265. [PubMed: 11306351]
- (8). Collins BE, Fralich TJ, Itonori S, Ichikawa Y, Schnaar RL. *Glycobiology.* 2000; 10:11. [PubMed: 10570219]
- (9). Mannori G, Crottet P, Cecconi O, Hanasaki K, Aruffo A, Nelson RM, Varki A, Bevilacqua MP. *Cancer Res.* 1995; 55:4425. [PubMed: 7545541]
- (10). St. Hill CA, Baharo-Hassan D, Farooqui M. *PLoS One.* 2011; 6
- (11). Izawa M, Kumamoto K, Mitsuoka C, Kanamori A, Ohmori K, Ishida H, Nakamura S, Kurata-Miura K, Sasaki K, Nishi T, Kannagi R. *Cancer Res.* 2000; 60:1410. [PubMed: 10728707]
- (12). Cazet A, Julien S, Bobowski M, Burchell J, Delannoy P. *Breast Cancer Res.* 2010; 12
- (13). Simanek EE, McGarvey GJ, Jablonowski JA, Wong CH. *Chem. Rev.* 1998; 98:833. [PubMed: 11848916]
- (14). Crich D, Dudkin V. *J. Am. Chem. Soc.* 2001; 123:6819. [PubMed: 11448186]
- (15). Overend WG, Rees CW, Sequeira JS. *J. Chem. Soc. (Resumed).* 1962:3429.
- (16). Ye D, Wang J, Zhang D, Feng E, Jiang H, Liu H. *Prog. Chem.* 22:91.
- (17). Nicolaou KC, Hummel CW, Bockovich NJ, Wong CH. *Chem. Commun.* 1991; 870
- (18). Danishefsky SJ, Gervay J, Peterson JM, McDonald FE, Koseki K, Griffith DA, Oriyama T, Marsden SP. *J. Am. Chem. Soc.* 1995; 117:1940.
- (19). Kiyoi T, Nakai Y, Kondo H, Ishida H, Kiso M, Hasegawa A. *Bioorg. Med. Chem.* 1996; 4:1167. [PubMed: 8879537]
- (20). Blixt O, Norberg T. *J. Org. Chem.* 1998; 63:2705. [PubMed: 11672140]
- (21). Lu D, Hu Y, He X, Sollogoub M, Zhang Y. *Carbohydr. Res.* 2014; 383:89. [PubMed: 24333940]
- (22). Pan Y, Chefalo P, Nagy N, Harding C, Guo Z. *J. Med. Chem.* 2005; 48:875. [PubMed: 15689172]
- (23). Yu H, Cheng J, Ding L, Khedri Z, Chen Y, Chin S, Lau K, Tiwari VK, Chen X. *J. Am. Chem. Soc.* 2009; 131:18467. [PubMed: 19947630]
- (24). Zheng M, Ye XS. *Tetrahedron.* 2012; 68:1475.
- (25). Ojeda R, de Paz JL, Barrientos AG, Martín-Lomas M, Penadés S. *Carbohydr. Res.* 2007; 342:448. [PubMed: 17173881]

- (26). Ratner DM, Adams EW, Disney MD, Seeberger PH. *ChemBioChem*. 2004; 5:1375. [PubMed: 15457538]
- (27). Werz DB, Seeberger PH. *Chem. Eur. J.* 2005; 11:3194. [PubMed: 15798968]
- (28). Szabó ZB, Borbás A, Bajza I, Lipták A. *Tetrahedron: Asymmetry*. 2005; 16:83.
- (29). Love KR, Seeberger PH. *J. Org. Chem.* 2005; 70:3168. [PubMed: 15822979]
- (30). Shimizu M, Togo H, Yokoyama M. *Synthesis*. 1998:799.
- (31). Toshima K. *Carbohydr. Res.* 2000; 327:15. [PubMed: 10968674]
- (32). Krag J, Christiansen MS, Petersen JG, Jensen HH. *Carbohydr. Res.* 2010; 345:872. [PubMed: 20304386]
- (33). De Paz JL, Ojeda R, Barrientos AG, Penadés S, Martín-Lomas M. *Tetrahedron: Asymmetry*. 2005; 16:149.
- (34). Hanashima S, Castagner B, Esposito D, Nokami T, Seeberger PH. *Org. Lett.* 2007; 9:1777. [PubMed: 17411062]
- (35). Lin CC, Huang KT, Lin CC. *Org. Lett.* 2005; 7:4169. [PubMed: 16146379]
- (36). Lin CC, Adak AK, Horng JC, Lin CC. *Tetrahedron*. 2009; 65:4714.
- (37). Yu B, Tao H. *Tetrahedron Lett.* 2001; 42:2405.
- (38). Adinolfi M, Barone G, Iadonisi A, Schiattarella M. *Tetrahedron Lett.* 2002; 43:5573.
- (39). Yu B, Sun J. *Chem. Commun.* 2010; 46:4668.
- (40). Mehta P, Cummings RD, McEver RPJ. *Biol. Chem.* 1998; 273:32506.
- (41). Wild MK, Huang MC, Schulze-Horsel U, Van der Merwe PA, Vestweber D. *J. Biol. Chem.* 2001; 276:31602. [PubMed: 11404363]
- (42). Beauharnois ME, Lindquist KC, Marathe D, Vanderslice P, Xia J, Matta KL, Neelamegham S. *Biochemistry*. 2005; 44:9507. [PubMed: 15996105]
- (43). Han J, Li X. *Carbohydr. Polym.* 2011; 83:137.

Scheme 1.
Target molecule and building blocks.

Scheme 2.

The fucosyl donor was selectively protected to support α glycosidic bond formation and to generate an acid stable α -fucoside linkage.

Scheme 3. Synthesis of the new glucosamine building block **17**.

Scheme 4.
Formation of disaccharide acceptor **III**.

Scheme 5.

Synthesis of donors **23** and **24** based on slight modification of the literature procedures (i: separate steps for de-*N*-acetylation and de-*O*-acetylation during preparation of **21**. ii: switching from 1*H*-tetrazole to imidazole in formation of phosphite donor **24**).^{30,31}

Scheme 6. Synthesis of *N*-trifluorobutyrylated sialic acid α(2-3) galactose.

Scheme 7.

Transformation of *N*-trifluorobutyrylated **30** to activated disaccharide donor **II**.

Scheme 8.

A final [2+2] glycosylation successfully assembles **I**.

Table 1

Summary of [2+2] glycosylation reactions performed under various conditions.

Entry	Promoter	Solvent	Temperature, (°C)	Yield (%)
1	TMSOTf ^{a, b}	DCM	0	0 ^c
2	TMSOTf ^{a, b}	DCE	rt	0 ^c
3	TfOH ^{a, b}	DCM	0	0 ^c
4	TfOH ^{a, b}	DCE	rt	0 ^c
5	Yb(OTf) ₃ ^{a, b}	DCE	0	10
6	Yb(OTf) ₃ ^{a, b}	DCE	rt	10
7	4 Å AW MS [*]	Toluene	rt	15
8	4 Å AW MS [*]	Toluene	MW 40 °C	15
9	BF ₃ ·Et ₂ O ^b	DCE	0	12
10	BF ₃ ·Et ₂ O ^b	DCE	rt	38
11	BF ₃ ·Et ₂ O ^b	DCE	MW 40 °C	0 ^d
12	BF ₃ ·Et ₂ O ^b	DCE	MW 60 °C	0 ^d

^a 0.01 equiv of promoter,^b 0.02 equiv promoter ,^c Both the donor and acceptor recovered unaltered,^d Hydrolysis of the donor is observed, rt ~ 25 °C^{*} AW MS : acid-washed molecular sieves.